Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 18 Hodgkin Disease 11 Lymphoma, Non-Hodgkin 4 Central Nervous System Neoplasms 4 Recurrence 3 Glioblastoma 3 Astrocytoma 3 Oligodendroglioma 2 Neurotoxicity Syndromes 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lymphoma, AIDS-Related 2 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Intraocular Lymphoma 1 HIV Infections 1 Gliosarcoma 1 Glioma 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

Rituximab 8 Cyclophosphamide 8 Peripheral Blood Stem Cell Transplantation 7 Methotrexate 7 fludarabine phosphate 6 Whole-Body Irradiation 5 Tacrolimus 5 Mycophenolic Acid 5 Dexamethasone 5 Cyclosporine 5 Cytarabine 4 Transplantation 3 Radiotherapy 3 Filgrastim 3 Busulfan 3 pegfilgrastim 2 merphos 2 etoposide phosphate 2 Methylprednisolone 2 Lenalidomide 2 Granulocyte Colony-Stimulating Factor 2 Etoposide 2 Carboplatin 2 Calcium Dobesilate 2 Antilymphocyte Serum 2 zanubrutinib 1 sodium thiosulfate 1 sargramostim 1 oblimersen 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Intraocular Lymphoma × Procarbazine × Clear all

NCT00074191 2017-04-21

Protocol-A

OHSU Knight Cancer Institute

Phase 2 Completed

Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡